Home LiteratureArticle Details
PMID: 1371955 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

Clinical and experimental immunology ·Vol. 87 ·No. 3 ·1992-03-00 ·Pages 415-21

Ratnoff WD, Knez JJ, Prince GM, Okada H, Lachmann PJ, Medof ME

Abstract

CD59, the membrane regulator of autologous C5b-9 channel formation, exhibits variable sensitivity to cleavage by phosphatidylinositol-specific phospholipase C (PI-PLC), an enzyme that releases glyco-inositolphospholipid (GPI)-anchored proteins from cell surfaces. To determine whether the GPI-anchor phospholipid of CD59 is similar to that of decay-accelerating factor (DAF) and whether variation in its structure underlies its variable enzyme susceptibility, the GPI anchors of the two proteins expressed on erythrocytes, polymorphonuclear and mononuclear leucocytes were compared in situ and after purification. Flow cytometric analyses of PI-PLC-treated cells showed parallel cell type specific release of both proteins as a function of enzyme concentration. Non-denaturing PAGE analyses of alkaline/hydroxylamine-treated proteins (affinity-purified from [125I]-surface-labelled cells) provided evidence for (i) comparable proportions of GPI-anchor acylation, and (ii) alkali-resistant rather than alkali-sensitive lipid substituents in erythrocytes. These findings argue that the differential C5b-9 sensitivity that distinguishes paroxysmal nocturnal haemoglobinuria II and III erythrocytes does not derive from expression of CD59 molecules with alternative GPI-anchor phospholipid structures.

MeSH Terms
Antigens, CD/chemistry Blood Proteins/chemistry CD55 Antigens CD59 Antigens Complement Inactivator Proteins/chemistry Complement Membrane Attack Complex/antagonists & inhibitors Electrophoresis, Polyacrylamide Gel Erythrocytes/drug effects Flow Cytometry Glycolipids/chemistry Glycosylphosphatidylinositols Humans Leukocytes, Mononuclear/drug effects Membrane Glycoproteins/chemistry Membrane Proteins/chemistry Neutrophils/drug effects Phosphatidylinositols/chemistry Structure-Activity Relationship Type C Phospholipases/pharmacology
Chemicals
Antigens, CD Blood Proteins CD55 Antigens CD59 Antigens Complement Inactivator Proteins Complement Membrane Attack Complex Glycolipids Glycosylphosphatidylinositols Membrane Glycoproteins Membrane Proteins Phosphatidylinositols Type C Phospholipases
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ratnoff W D
Institute of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Knez J J
Prince G M
Okada H
Lachmann P J
Medof M E
References (55)
55 references, click to expand
  1. Variations in the red cells in paroxysmal nocturnal haemoglobinuria.
    Br J Haematol. 1973 Mar;24(3):327-42 PMID: 4713634
  2. Inhibition of complement by a substance isolated from human erythrocytes. I. Extraction from human erythrocyte stromata.
    Immunochemistry. 1969 May;6(3):391-403 PMID: 5786933
  3. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    J Exp Med. 1984 Nov 1;160(5):1558-78 PMID: 6238120
  4. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    J Clin Invest. 1979 Aug;64(2):428-33 PMID: 457861
  5. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.
    Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57 PMID: 637870
  6. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein.
    Blood. 1990 Jan 1;75(1):284-9 PMID: 1688497
  7. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement.
    J Immunol. 1989 Oct 1;143(7):2262-6 PMID: 2476502
  8. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
    J Clin Invest. 1989 Nov;84(5):1387-94 PMID: 2478585
  9. A human immunoglobulin G receptor exists in both polypeptide-anchored and phosphatidylinositol-glycan-anchored forms.
    Proc Natl Acad Sci U S A. 1989 Jul;86(13):5079-83 PMID: 2525780
  10. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions.
    J Exp Med. 1989 Aug 1;170(2):481-97 PMID: 2526846
  11. Different membrane anchors of Fc gamma RIII (CD16) on K/NK-lymphocytes and neutrophils. Protein- vs lipid-anchor.
    J Immunol. 1989 Aug 15;143(4):1274-7 PMID: 2545784
  12. Amino-terminal amino acid sequence and chemical and functional properties of a membrane attack complex-inhibitory factor from human erythrocyte membranes.
    J Biochem. 1989 Oct;106(4):589-92 PMID: 2606912
  13. Complete deficiency of 20 KDa homologous restriction factor (HRF20) and restoration with purified HRF20.
    Biochem Biophys Res Commun. 1989 Oct 16;164(1):468-73 PMID: 2803313
  14. Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C.
    J Biol Chem. 1988 Dec 15;263(35):18766-75 PMID: 2848806
  15. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol.
    Mol Immunol. 1989 Feb;26(2):153-61 PMID: 2918859
  16. The Fc gamma receptor of natural killer cells is a phospholipid-linked membrane protein.
    Nature. 1988 Jun 9;333(6173):568-70 PMID: 2967436
  17. The PI-linked receptor FcRIII is released on stimulation of neutrophils.
    Nature. 1988 Jun 16;333(6174):667-9 PMID: 2967437
  18. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF).
    J Immunol. 1986 Aug 15;137(4):1275-9 PMID: 3090145
  19. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2.
    Nature. 1987 Oct 29-Nov 4;329(6142):840-2 PMID: 3313052
  20. Demonstration of phosphatidylinositol anchors on Ly-6 molecules by specific phospholipase C digestion and gel electrophoresis in octylglucoside.
    Biochem Biophys Res Commun. 1987 Nov 13;148(3):1304-11 PMID: 3318830
  21. Biosynthesis of placental alkaline phosphatase and its post-translational modification by glycophospholipid for membrane-anchoring.
    J Biol Chem. 1988 Feb 25;263(6):3016-21 PMID: 3343238
  22. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  23. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  24. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4 PMID: 6225118
  25. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.
    Blood. 1983 Oct;62(4):873-82 PMID: 6349718
  26. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.
    Int Immunol. 1989;1(2):205-8 PMID: 2487685
  27. Conversion of human erythrocyte acetylcholinesterase from an amphiphilic to a hydrophilic form by phosphatidylinositol-specific phospholipase C and serum phospholipase D.
    Eur J Biochem. 1989 Apr 1;180(3):503-8 PMID: 2540962
  28. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system.
    Blood. 1985 May;65(5):1237-44 PMID: 2581636
  29. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    J Clin Invest. 1989 Jul;84(1):7-17 PMID: 2738160
  30. Structural characterization of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase by fast atom bombardment mass spectrometry.
    J Biol Chem. 1988 Dec 15;263(35):18776-84 PMID: 2848807
  31. The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria.
    Nature. 1988 Jun 9;333(6173):565-7 PMID: 2967435
  32. Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures.
    Annu Rev Biochem. 1988;57:285-320 PMID: 3052274
  33. Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.
    J Exp Med. 1987 Oct 1;166(4):1011-25 PMID: 3309123
  34. Anchoring mechanisms for LFA-3 cell adhesion glycoprotein at membrane surface.
    Nature. 1987 Oct 29-Nov 4;329(6142):846-8 PMID: 3313053
  35. Synthesis of aberrant decay-accelerating factor proteins by affected paroxysmal nocturnal hemoglobinuria leukocytes.
    J Clin Invest. 1990 Jan;85(1):47-54 PMID: 1688570
  36. Structural basis for variations in the sensitivity of human decay accelerating factor to phosphatidylinositol-specific phospholipase C cleavage.
    J Immunol. 1990 Feb 1;144(3):1030-6 PMID: 1688588
  37. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement.
    Cell Immunol. 1990 Mar;126(1):176-84 PMID: 1689219
  38. Analysis of PI (phosphatidylinositol)-anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement-regulatory factor.
    FEBS Lett. 1990 Feb 12;261(1):142-6 PMID: 1689670
  39. Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells.
    Immunology. 1990 Mar;69(3):396-401 PMID: 1690178
  40. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    J Immunol. 1990 May 1;144(9):3478-83 PMID: 1691760
  41. Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis.
    J Exp Med. 1990 Jul 1;172(1):367-70 PMID: 1694224
  42. Glycolipid anchoring of plasma membrane proteins.
    Annu Rev Cell Biol. 1990;6:1-39 PMID: 2148872
  43. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria.
    Blood. 1990 Apr 15;75(8):1595-601 PMID: 2183885
  44. Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids.
    Biochem J. 1990 Jan 15;265(2):471-7 PMID: 2302178
  45. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
    J Exp Med. 1985 Jul 1;162(1):75-92 PMID: 2409211
  46. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor.
    J Immunol. 1986 Mar 1;136(5):1772-6 PMID: 2419413
  47. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
    J Exp Med. 1986 May 1;163(5):1150-61 PMID: 2422313
  48. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.
    Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975-9 PMID: 2428045
  49. Increased expression of complement decay-accelerating factor during activation of human neutrophils.
    J Clin Invest. 1987 Jan;79(1):214-20 PMID: 2432089
  50. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.
    Biochemistry. 1986 Nov 4;25(22):6740-7 PMID: 2432921
  51. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
    J Clin Invest. 1987 Jul;80(1):165-74 PMID: 2439544
  52. Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.
    Proc Natl Acad Sci U S A. 1988 Feb;85(3):880-4 PMID: 2448783
  53. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.
    J Biochem. 1988 Oct;104(4):633-7 PMID: 2467907
  54. A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. Comparison of the roles of H19 and LFA-3 molecules in T cell activation.
    J Immunol. 1989 May 1;142(9):3013-20 PMID: 2468708
  55. CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
    J Exp Med. 1989 Sep 1;170(3):637-54 PMID: 2475570
Article Info
Journal
Clinical and experimental immunology
Abbr.
Clin Exp Immunol
ISSN
0009-9104
DOI
10.1111/j.1365-2249.1992.tb03012.x
Published
1992-03-00
Pages
415-21
Language
English
Region
England
NLM ID
0057202
PMCID
PMC1554345
Subset
IM
Grants
NIAID NIH HHS · AI23598 · United States
NIDDK NIH HHS · P01DK38181 · United States
External Links
PubMed source DOI: 10.1111/j.1365-2249.1992.tb03012.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2